Skip to main content

Deborah Mulford, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-9484

Office: (585) 275-5823

Fax: (585) 784-7907

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



I was drawn to the field of oncology because it allows me to treat the whole person. The number of new and effective cancer therapies we can offer patients excites me, and it is incredibly rewarding to experience positive results with patients and families.

My practice style is patient- and family-focused. I work closely with a multidisciplinary team to determine the best, evidence-based treatment option for each individual. My primary focus is in the treatment of cancers originating from the lung and/or head and neck region. I am a native Rochesterian and am proud to have attended the University of Rochester for medical school.

Conditions I Treat:

- Non small cell lung cancer
- Small cell lung cancer
- Neuroendocrine carcinoma
- Mesothelioma
- Head and neck malignancies
- Thyroid cancer
- Other malignancies




    MD | University of Rochester

    Post-doctoral Training & Residency

    07/01/2002 - 06/30/2005
    Fellowship in Hematology & Oncology at Memorial Sloan-Kettering Cancer Center

    07/01/2000 - 06/30/2002
    Residency in Internal Medicine at New York University Langone Medical Center-GME

    07/01/1999 - 06/30/2000
    Internship in Internal Medicine at New York University Langone Medical Center-GME

    VIEW ALL expand_more


    2004 - 2006
    NIH Clinical Loan Repayment Program
    Sponsor: NIH

    2003 - 2005
    Lauri Strauss Leukemia Foundation Endowed Fellowship
    Sponsor: Lauri Strauss Leukemia Foundation
    Location: Memorial Sloan-Kettering Cancer Center, New York City, NY

    2003 - 2005
    Mortimer J. Lacher Fellowship Award
    Location: Memorial Sloan-Kettering Cancer Center, New York City, NY

    1996 - 1996
    International Cancer Fellowship
    Sponsor: University of Rochester Medical School
    Location: Rochester, NY

    U.S. and European Patent-Photographic Apparatus for an Optical Instrument
    Location: Polaroid Corporation, Boston, MA

    Warner King Prize
    Location: Union College, Schenectady, NY

    1989 - 1990
    Stearns Prize
    Location: Union College, Schenectady, NY

    1988 - 1990
    Eta Kappa Nu and Tau Beta Pi Engineering Honor Societies
    Location: Union College, Schenectady, NY

    1986 - 1990
    Tidmarsh Scholarship for Piano
    Location: Union College, Schenectady, NY

    VIEW ALL expand_more

    Clinical Trials

    Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

    Lead Researcher: Deborah Mulford MD

    This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.

    View Study Details


    Journal Articles

    Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani AS, Winter AM, Winter JN, Gordon LI, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM. "Response-Adapted, Time-Limited Venetoclax, Umbralisib and Ublituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia." Blood advances.. 2023 Oct 23; Epub 2023 Oct 23.

    Lissa D, Takahashi N, Desai P, Manukyan I, Schultz CW, Rajapakse V, Velez MJ, Mulford D, Roper N, Nichols S, Vilimas R, Sciuto L, Chen Y, Guha U, Rajan A, Atkinson D, El Meskini R, Weaver Ohler Z, Thomas A. "Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models." Nature communications.. 2022 Apr 19; 13(1):2023. Epub 2022 Apr 19.

    Roper N, Velez MJ, Chiappori A, Kim YS, Wei JS, Sindiri S, Takahashi N, Mulford D, Kumar S, Ylaya K, Trindade C, Manukyan I, Brown AL, Trepel JB, Lee JM, Hewitt S, Khan J, Thomas A. "Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer." Nature communications.. 2021 Jun 23; 12(1):3880. Epub 2021 Jun 23.

    Books & Chapters

    Chapter Title: Monoclonal Antibody Therapies of Cancer
    Book Title: Cancer Chemotherapy and Biotherapy
    Author List: Scheinberg DA, Mulford DA, Jurcic JG, Junghans RP, Sgouros G.
    Published By: Baltimore: Lippincott, Williams, And Wilkins 2006



    At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.